Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
DXCM [NASD]
DexCom, Inc.
Index- P/E- EPS (ttm)-0.43 Insider Own2.90% Shs Outstand74.92M Perf Week-8.08%
Market Cap2.74B Forward P/E263.38 EPS next Y0.14 Insider Trans22.56% Shs Float73.23M Perf Month1.05%
Income-31.20M PEG- EPS next Q-0.10 Inst Own95.10% Short Float6.66% Perf Quarter1.55%
Sales177.50M P/S15.45 EPS this Y46.80% Inst Trans0.14% Short Ratio5.55 Perf Half Y-0.08%
Book/sh1.23 P/B29.76 EPS next Y142.40% ROA-27.10% Target Price41.90 Perf Year55.99%
Cash/sh0.77 P/C47.78 EPS next 5Y32.50% ROE-38.90% 52W Range21.76 - 49.83 Perf YTD3.39%
Dividend- P/FCF- EPS past 5Y26.80% ROI-31.80% 52W High-26.53% Beta0.39
Dividend %- Quick Ratio2.90 Sales past 5Y74.80% Gross Margin63.90% 52W Low68.24% ATR1.30
Employees646 Current Ratio3.20 Sales Q/Q59.10% Oper. Margin-17.10% RSI (14)45.69 Volatility4.59% 3.35%
OptionableYes Debt/Eq0.07 EPS Q/Q-6.30% Profit Margin-17.60% Rel Volume0.61 Prev Close35.93
ShortableYes LT Debt/Eq0.05 EarningsAug 04 Payout- Avg Volume879.40K Price36.61
Recom2.10 SMA20-5.73% SMA503.45% SMA2001.91% Volume533,658 Change1.89%
17-Jun-14Reiterated Canaccord Genuity Buy $38 → $40
24-Jan-14Resumed Canaccord Genuity Buy $34 → $44
14-Jan-14Reiterated The Benchmark Company Buy $40 → $44
07-Nov-13Upgrade Northland Capital Under Perform → Market Perform
15-Oct-13Initiated The Benchmark Company Buy $37
12-Aug-13Reiterated Feltl & Co. Sell $16.50 → $18.25
08-Aug-13Reiterated Canaccord Genuity Buy $25 → $26
24-Jul-13Downgrade Northland Capital Outperform → Under Perform $17
13-Jun-13Downgrade Feltl & Co. Hold → Sell
10-Jun-13Downgrade Wunderlich Buy → Hold $20
13-Mar-13Reiterated Wunderlich Buy $18 → $20
25-Feb-13Reiterated Feltl & Co. Hold $14 → $15.50
14-Jan-13Reiterated Wunderlich Buy $15 → $18
18-Oct-12Initiated Northland Securities Market Perform $12
17-Jan-12Initiated Brean Murray Buy $12.50
11-Jan-12Downgrade MLV & Co Buy → Hold $9
29-Dec-11Initiated Wunderlich Buy $12
20-Dec-11Initiated MLV & Co Buy $11
28-Oct-11Downgrade Feltl & Co. Buy → Hold
16-Aug-11Upgrade Feltl & Co. Hold → Buy $15.85 → $15.35
07-Jul-14 08:30AM  DEXCOM INC Files SEC form 8-K, Entry into a Material Definitive Agreement EDGAR Online
16-Jun-14 02:30PM  DexCom Collaborates with Insulet Corporation Zacks +5.08%
02:30PM  DexCom Collaborates with Insulet Corporation
12:00AM  Freedom for Diabetics as Bionic Pancreas Passes Testing at Bloomberg
12:00AM  Freedom for Diabetics as Bionic Pancreas Passes Testing
15-Jun-14 09:00PM  Diabetics Get Freedom in Bionic Pancreas Real-World Trial at Bloomberg
09:00PM  Diabetics Get Freedom in Bionic Pancreas Real-World Trial
13-Jun-14 04:01PM  DexComs Forthcoming Mobile App Platform to Integrate Data from Insulets OmniPod System Business Wire
04:01PM  DexComs Forthcoming Mobile App Platform to Integrate Data from Insulets OmniPod System
05-Jun-14 09:17AM  Top Swing Trade Ideas for Thursday, June 5: DexCom, Conn's and More at TheStreet
09:17AM  Top Swing Trade Ideas for Thursday, June 5: DexCom, Conn's and More
04-Jun-14 05:15PM  [video] Health app space heats up at CNBC +7.06%
05:15PM  [video] Health app space heats up
12:50PM  FDA Nod for DexCom's G4 PLATINUM System Zacks
12:50PM  FDA Nod for DexCom's G4 PLATINUM System
08:30AM  DEXCOM INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders EDGAR Online
08:30AM  DEXCOM INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
03-Jun-14 04:01PM  The first and only real-time professional CGM, the Dexcom G4® PLATINUM Professional Continuous Glucose Monitoring System (CGM) Receives FDA Approval Business Wire
04:01PM  The first and only real-time professional CGM, the Dexcom G4® PLATINUM Professional Continuous Glucose Monitoring System (CGM) Receives FDA Approval
27-May-14 08:30AM  DexCom Announces Upcoming Conference Presentations Business Wire
08:30AM  DexCom Announces Upcoming Conference Presentations
16-May-14 03:55PM  Why Jim Cramer Says Investors Should Watch DexCom (DXCM) Stock at TheStreet
11:45AM  [video] Jim Cramer on Why DexCom Could be a Good Portfolio Addition at TheStreet
11:37AM  The Bellwether We've Searched For at TheStreet
12-May-14 10:27AM  DexCom has a conference call hosted by JPMorgan at theflyonthewall.com
09-May-14 01:04PM  DEXCOM INC Financials EDGAR Online Financials
06-May-14 08:32AM  DexCom Misses, Sees Broader Q1 Loss Zacks
02-May-14 02:11PM  Why DexCom Inc. Shares Briefly Swooned at Motley Fool
01-May-14 08:55PM  DexCom's CEO Discusses Q1 2014 Results - Earnings Call Transcript at Seeking Alpha
04:30PM  DEXCOM INC Earnings Call scheduled for 4:30 pm ET today CCBN
04:25PM  DexCom, Inc. Discusses Q1 2014 Results (Webcast) at Seeking Alpha
04:09PM  DEXCOM INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online
04:01PM  DexCom, Inc. Reports First Quarter 2014 Financial Results Business Wire
07:34AM  DEXCOM INC Earnings Call scheduled for 4:30 pm ET today CCBN
07:07AM  Q1 2014 DEXCOM INC Earnings Release - After Market Close CCBN
30-Apr-14 03:37PM  5 stocks to watch at MarketWatch
08:30AM  DexCom Announces Upcoming Conference Presentations Business Wire
24-Apr-14 08:30AM  DexCom Schedules First Quarter 2014 Earnings Release and Conference Call for May 1, 2014 at 4:30 p.m. Eastern Time Business Wire
16-Apr-14 01:09PM  1 Stock Helping Revolutionize Diabetes Monitoring at Motley Fool +5.47%
15-Apr-14 06:46PM  Lightning Round: Delta, LinkedIn & More at CNBC
10-Apr-14 01:50PM  Delcath Systems Shares Tank on Stock Split Zacks -5.83%
09:50AM  Why DexCom (DXCM) Stock Is Higher Today at TheStreet
08:10AM  Top Analyst Upgrades and Downgrades: Apple, EMC, Facebook, Twitter, IBM , AcelRx and More at 24/7 Wall St.
08:10AM  Top Analyst Upgrades and Downgrades: Apple, EMC, Facebook, Twitter, IBM , AcelRx and More 24/7 Wall St.
05:54AM  DexCom upgraded to Buy from Neutral at Sterne Agee theflyonthewall.com
08-Apr-14 07:56AM  DexCom (DXCM) is now in Oversold Territory Zacks
03-Apr-14 02:30PM  DexCom Shares Fall on FDA Warning Zacks
01-Apr-14 01:50PM  Balanced View on Haemonetics Zacks
31-Mar-14 01:50PM  Balanced View on Hologic Zacks
25-Mar-14 04:02PM  Should You Buy DexCom After The Meteoric Rise? at Seeking Alpha
09:32AM  [$$] Suicide Banker Feared Investigation at The Wall Street Journal
08:30AM  DexCom Receives FDA Warning Letter for Administrative Deficiencies in its MDR Reporting Business Wire
24-Mar-14 07:12AM  Why DexCom (DXCM) Could Be a Potential Winner Zacks
05-Mar-14 04:04PM  Dexcom Supports NASCAR Driver Ryan Reeds American Diabetes Association Drive to Stop Diabetes Initiative Business Wire
04:04PM  Dexcom Supports NASCAR Driver Ryan Reeds American Diabetes Association Drive to Stop Diabetes Initiative
04-Mar-14 06:23AM  Is DexCom (DXCM) a Great Growth Stock? Zacks
06:23AM  Is DexCom (DXCM) a Great Growth Stock?
28-Feb-14 11:45AM  Insider Trading Alert - WAB, DXCM And CMCSA Traded By Insiders at TheStreet
26-Feb-14 01:04PM  DEXCOM INC Financials EDGAR Online Financials
25-Feb-14 08:40AM  DexCom Beats, Sees Narrower Q4 Loss Zacks
08:40AM  DexCom Beats, Sees Narrower Q4 Loss
08:30AM  DexCom Announces Upcoming Conference Presentations Business Wire
08:30AM  DexCom Announces Upcoming Conference Presentations
21-Feb-14 07:54AM  DexCom price target raised to $50 from $45 at Stephens at theflyonthewall.com
07:54AM  DexCom price target raised to $50 from $45 at Stephens
20-Feb-14 08:56PM  DexCom's CEO Discusses Q4 2013 Results - Earnings Call Transcript Optionetics
08:56PM  DexCom's CEO Discusses Q4 2013 Results - Earnings Call Transcript at Seeking Alpha
08:56PM  DexCom's CEO Discusses Q4 2013 Results - Earnings Call Transcript
04:30PM  DEXCOM INC Earnings Call scheduled for 4:30 pm ET today CCBN
04:25PM  DexCom, Inc. Discusses Q4 2013 Results (Webcast) Optionetics
04:25PM  DexCom, Inc. Discusses Q4 2013 Results (Webcast) at Seeking Alpha
04:25PM  DexCom, Inc. Discusses Q4 2013 Results (Webcast)
04:16PM  DEXCOM INC Files SEC form 8-K, Results of Operations and Financial Condition, Change in Directors or Principal Office EDGAR Online
04:01PM  DexCom, Inc. Reports Fourth Quarter and Full Year 2013 Financial Results Business Wire
07:34AM  DEXCOM INC Earnings Call scheduled for 4:30 pm ET today CCBN
07:07AM  Q4 2013 DEXCOM INC Earnings Release - After Market Close CCBN
14-Feb-14 07:58AM  Can the Rally in DexCom (DXCM) Shares Continue? Zacks
10-Feb-14 05:54AM  Fluidigm Corporation (FLDM) Crumbles: Stock Falls by 6.4% Zacks +5.36%
05:54AM  Fluidigm Corporation (FLDM) Crumbles: Stock Falls by 6.4% Zacks
05:54AM  Fluidigm Corporation (FLDM) Crumbles: Stock Falls by 6.4% Zacks
05:50AM  Fluidigm Corporation (FLDM) Crumbles: Stock Falls by 6.4% Zacks
06-Feb-14 04:10PM  FDA Approval for DexCom's G4 PLATINUM Zacks
08:30AM  DexCom to Present at Leerink Global Healthcare Conference 2014 Business Wire
08:30AM  DexCom Schedules Fourth Quarter and Full Year 2013 Earnings Release and Conference Call for February 20, 2014 at 4:30 p.m. Eastern Time Business Wire
05-Feb-14 08:38PM  DXCM: Improving the Quality of Life for Children With Diabetes at TheStreet
04-Feb-14 06:35PM  Lightning Round: Coca-Cola, Valero & More at CNBC
09:00AM  What to Watch at DexCom, Smith & Nephew, and Endo Health Solutions This Morning at Motley Fool
03-Feb-14 06:56PM  On The Fly: After Hours Movers at theflyonthewall.com
05:57PM  Innovative Dexcom G4® PLATINUM Continuous Glucose Monitor (CGM) Receives FDA Approval for Use in Children Ages 2 to 17 Years Business Wire
23-Jan-14 11:36AM  Commit To Buy DexCom At $30, Earn 11.4% Annualized Using Options at TheStreet
11:36AM  Commit To Buy DexCom At $30, Earn 11.4% Annualized Using Options
20-Jan-14 06:08AM  Why DexCom (DXCM) Could Beat Earnings Estimates Again Zacks
06:08AM  Why DexCom (DXCM) Could Beat Earnings Estimates Again
16-Jan-14 08:31AM  3 Ways Johnson & Johnson Is Revolutionizing Diabetes Care at Motley Fool
08:31AM  3 Ways Johnson & Johnson Is Revolutionizing Diabetes Care
15-Jan-14 09:55AM  Brokerage says pro-Obamacare stocks are up 52% in the past year at MarketWatch
09:55AM  Brokerage says pro-Obamacare stocks are up 52% in the past year
14-Jan-14 08:31AM  DEXCOM INC Files SEC form 8-K, Results of Operations and Financial Condition EDGAR Online
08:31AM  DEXCOM INC Files SEC form 8-K, Results of Operations and Financial Condition
13-Jan-14 03:20PM  Dexcoms Innovative Diabetes Monitoring Device Recognized For Outstanding Achievement at Consumer Electronics Show (CES) Business Wire
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring systems. It offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers in the hospital for the treatment of patients with and without diabetes. The company's ambulatory product line includes SEVEN PLUS, DexCom G4 system, and DexCom G4 PLATINUM system for adults with diabetes to detect trends and track glucose patterns, to aid in the detection of hypoglycemia and hyperglycemia, and to facilitate acute and long-term therapy adjustments, as well as DexCom SHARE, a remote monitoring system, which provides secondary notification and does not replace real time continuous glucose monitoring or standard home blood glucose monitoring. Its in-hospital product line comprises GlucoClear, a blood-based in-vivo automated glucose monitoring system for use by healthcare providers in the hospital. The company also offers SweetSpot, a software platform that enables patients to aggregate and analyze data from diabetes devices and to share it with their healthcare providers. It markets its products directly to endocrinologists, physicians, and diabetes educators primarily in the United States. The company was founded in 1999 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
VALDES JORGE ACTOJul 08Option Exercise3.1916,00051,040233,487Jul 09 06:49 PM
VALDES JORGE ACTOJul 08Sale36.6616,000586,506217,487Jul 09 06:49 PM
Balo Andrew KSVP, Regulatory and ClinicalJun 25Option Exercise8.9410,00089,400169,099Jun 25 08:35 PM
Balo Andrew KSVP, Regulatory and ClinicalJun 25Sale40.6010,000405,982159,099Jun 25 08:35 PM
DOUBLEDAY RICHARDSr. VP. Worldwide SalesJun 23Option Exercise6.034,00024,120130,136Jun 25 08:34 PM
DOUBLEDAY RICHARDSr. VP. Worldwide SalesJun 23Sale40.984,000163,925126,136Jun 25 08:34 PM
SKYLER JAY SDirectorJun 20Sale40.0030,0001,200,000145,884Jun 23 06:10 PM
SKYLER JAY SDirectorJun 19Sale40.0030,0001,200,000175,884Jun 23 06:10 PM
ROPER JESSVP, CFOJun 18Option Exercise7.698,00061,51094,286Jun 18 07:10 PM
ROPER JESSVP, CFOJun 18Sale39.178,000313,33387,786Jun 18 07:10 PM
GREGG TERRANCE HCEOJun 16Option Exercise6.8525,000171,250420,626Jun 18 07:11 PM
GREGG TERRANCE HCEOJun 16Sale37.2325,000930,800395,626Jun 18 07:11 PM
GREGG TERRANCE HCEOJun 16Sale37.2310,000372,320672,889Jun 18 07:11 PM
LISTER JOHNSr. VP, General CounselJun 12Option Exercise4.581,7508,015117,658Jun 13 05:01 PM
LISTER JOHNSr. VP, General CounselJun 12Sale36.133,500126,455115,908Jun 13 05:01 PM
Balo Andrew KSVP, Regulatory and ClinicalJun 11Option Exercise8.9410,00089,400166,483Jun 13 04:58 PM
Balo Andrew KSVP, Regulatory and ClinicalJun 11Sale36.6310,000366,305159,099Jun 13 04:58 PM
VALDES JORGE ACTOJun 09Option Exercise3.1916,00051,040233,487Jun 11 04:42 PM
VALDES JORGE ACTOJun 09Sale36.6816,000586,866217,487Jun 11 04:42 PM
DOUBLEDAY RICHARDSr. VP. Worldwide SalesJun 05Option Exercise6.034,00024,120130,136Jun 06 05:17 PM
DOUBLEDAY RICHARDSr. VP. Worldwide SalesJun 05Sale35.594,000142,356126,136Jun 06 05:17 PM
Balo Andrew KSVP, Regulatory and ClinicalMay 27Option Exercise7.2510,00072,500169,099May 28 07:45 PM
Balo Andrew KSVP, Regulatory and ClinicalMay 27Sale33.8610,000338,638159,099May 28 07:45 PM
Pacelli Steven RobertEVP, Strategy & Corp. Dev.May 23Option Exercise7.2514,000101,500255,399May 28 07:55 PM
Pacelli Steven RobertEVP, Strategy & Corp. Dev.May 23Sale32.7614,000458,632241,399May 28 07:55 PM
ROPER JESSVP, CFOMay 19Option Exercise4.718,00037,70092,784May 19 07:14 PM
ROPER JESSVP, CFOMay 19Sale32.208,000257,57687,786May 19 07:14 PM
GREGG TERRANCE HCEOMay 15Option Exercise6.8525,000171,250420,626May 19 07:10 PM
GREGG TERRANCE HCEOMay 15Sale31.1510,000311,472682,889May 19 07:10 PM
GREGG TERRANCE HCEOMay 15Sale31.1525,000778,650395,626May 19 07:10 PM
LISTER JOHNSr. VP, General CounselMay 12Option Exercise4.581,7508,015121,158May 14 04:50 PM
Balo Andrew KSVP, Regulatory and ClinicalMay 12Option Exercise7.2510,00072,500169,099May 14 04:52 PM
LISTER JOHNSr. VP, General CounselMay 12Sale31.523,500110,320117,658May 14 04:50 PM
Balo Andrew KSVP, Regulatory and ClinicalMay 12Sale31.7510,000317,499159,099May 14 04:52 PM
VALDES JORGE ACTOMay 08Option Exercise3.1916,00051,040233,487May 12 05:33 PM
VALDES JORGE ACTOMay 08Sale29.8316,000477,331217,487May 12 05:33 PM
Balo Andrew KSVP, Regulatory and ClinicalApr 25Option Exercise7.2510,00072,500169,099Apr 29 05:04 PM
MOY JEFFREYSVP, OperationsApr 25Option Exercise8.315,09742,350146,662Apr 29 05:09 PM
Balo Andrew KSVP, Regulatory and ClinicalApr 25Sale34.3510,000343,460159,099Apr 29 05:04 PM
Pacelli Steven RobertEVP, Strategy & Corp. Dev.Apr 23Option Exercise7.2514,000101,500255,399Apr 25 05:30 PM
DOUBLEDAY RICHARDSr. VP. Worldwide SalesApr 23Option Exercise6.034,00024,120151,523Apr 25 04:32 PM
Pacelli Steven RobertEVP, Strategy & Corp. Dev.Apr 23Sale35.9014,000502,663241,399Apr 25 05:30 PM
DOUBLEDAY RICHARDSr. VP. Worldwide SalesApr 23Sale35.924,000143,689147,523Apr 25 04:32 PM
ROPER JESSVP, CFOApr 21Option Exercise3.198,00025,52095,786Apr 23 04:56 PM
ROPER JESSVP, CFOApr 21Sale36.188,000289,47187,786Apr 23 04:56 PM
GREGG TERRANCE HCEOApr 15Option Exercise6.8525,000171,250420,626Apr 16 07:45 PM
GREGG TERRANCE HCEOApr 15Sale34.0925,000852,145395,626Apr 16 07:45 PM
GREGG TERRANCE HCEOApr 15Sale34.0910,000340,858692,889Apr 16 07:45 PM
LISTER JOHNSr. VP, General CounselApr 14Option Exercise4.581,7508,015122,292Apr 16 07:57 PM
LISTER JOHNSr. VP, General CounselApr 14Sale35.862,884103,420119,408Apr 16 07:57 PM
Balo Andrew KSVP, Regulatory and ClinicalApr 11Option Exercise7.2510,00072,500169,099Apr 15 06:30 PM
Balo Andrew KSVP, Regulatory and ClinicalApr 11Sale35.3610,000353,564159,099Apr 15 06:30 PM
VALDES JORGE ACTOApr 08Option Exercise3.1916,00051,040233,487Apr 10 06:32 PM
VALDES JORGE ACTOApr 08Sale35.9916,000575,898217,487Apr 10 06:32 PM
MOY JEFFREYSVP, OperationsApr 07Option Exercise6.336,46440,914141,565Apr 09 08:48 PM
SKYLER JAY SDirectorApr 01Sale41.2930,0001,238,799205,884Apr 03 04:42 PM
MOY JEFFREYSVP, OperationsMar 27Option Exercise6.3315,00094,950233,017Mar 31 07:47 PM
SKYLER JAY SDirectorMar 26Sale43.0530,0001,291,458235,884Mar 28 08:30 PM
Balo Andrew KSVP, Regulatory and ClinicalMar 25Option Exercise7.2510,00072,500169,099Mar 26 04:43 PM
Balo Andrew KSVP, Regulatory and ClinicalMar 25Sale43.0010,000429,964159,099Mar 26 04:43 PM
Pacelli Steven RobertEVP, Strategy & Corp. Dev.Mar 24Option Exercise7.2514,000101,500255,399Mar 26 04:43 PM
Pacelli Steven RobertEVP, Strategy & Corp. Dev.Mar 24Sale42.9214,000600,814241,399Mar 26 04:43 PM
ROPER JESSVP, CFOMar 18Option Exercise3.198,00025,52095,786Mar 20 05:25 PM
VALDES JORGE ACTOMar 18Option Exercise13.4527,100364,495217,487Mar 20 05:25 PM
ROPER JESSVP, CFOMar 18Sale46.008,000368,00087,786Mar 20 05:25 PM
GREGG TERRANCE HCEOMar 17Option Exercise6.8525,000171,250420,626Mar 17 08:28 PM
GREGG TERRANCE HCEOMar 17Sale44.7110,000447,100702,889Mar 17 08:28 PM
GREGG TERRANCE HCEOMar 17Sale45.5325,0001,138,250395,626Mar 17 08:28 PM
LORD JONATHAN T MDDirectorMar 13Option Exercise7.7836,000280,080164,310Mar 17 08:10 PM
GREGG TERRANCE HCEOMar 13Option Exercise8.9510,00089,500405,626Mar 17 08:28 PM
GREGG TERRANCE HCEOMar 13Sale45.0910,000450,895395,626Mar 17 08:28 PM
LORD JONATHAN T MDDirectorMar 13Sale45.0536,0001,621,800128,310Mar 17 08:10 PM
GREGG TERRANCE HCEOMar 12Option Exercise8.9520,000179,000415,626Mar 13 07:28 PM
LISTER JOHNGeneral Counsel, VP of HRMar 12Option Exercise4.581,7508,015129,700Mar 14 08:51 PM
GREGG TERRANCE HCEOMar 12Sale45.3820,000907,586395,626Mar 13 07:28 PM
LISTER JOHNGeneral Counsel, VP of HRMar 12Sale45.259,158414,433120,542Mar 14 08:51 PM
VALDES JORGE ACTOMar 11Option Exercise13.4523,437315,228226,440Mar 13 07:09 PM
Balo Andrew KSVP, Regulatory and ClinicalMar 11Option Exercise7.2510,00072,500172,961Mar 13 07:12 PM
DOUBLEDAY RICHARDSr. VP. Worldwide SalesMar 11Option Exercise6.0350,000301,500202,443Mar 13 07:20 PM
GREGG TERRANCE HCEOMar 11Option Exercise8.9510,00089,500405,626Mar 13 07:28 PM
GREGG TERRANCE HCEOMar 11Sale45.7510,000457,500395,626Mar 13 07:28 PM
DOUBLEDAY RICHARDSr. VP. Worldwide SalesMar 11Sale46.4250,0002,321,245152,443Mar 13 07:20 PM
Balo Andrew KSVP, Regulatory and ClinicalMar 11Sale45.9310,000459,267167,907Mar 13 07:12 PM
VALDES JORGE ACTOMar 11Sale46.1823,4371,082,328203,003Mar 13 07:09 PM
VALDES JORGE ACTOMar 10Option Exercise3.1916,00051,040231,853Mar 11 08:52 PM
VALDES JORGE ACTOMar 10Sale46.5716,000745,120215,853Mar 11 08:52 PM
GREGG TERRANCE HCEOMar 06Option Exercise7.6720,500157,225225,313Mar 10 08:51 PM
GREGG TERRANCE HCEOMar 06Sale47.8220,500980,320212,813Mar 10 08:51 PM
MOY JEFFREYSVP, OperationsMar 05Option Exercise6.335,00031,650192,485Mar 06 07:54 PM
GREGG TERRANCE HCEOMar 05Option Exercise6.5966,890440,766272,813Mar 06 08:00 PM
MOY JEFFREYSVP, OperationsMar 05Sale47.505,000237,500187,485Mar 06 07:54 PM
GREGG TERRANCE HCEOMar 05Sale47.9166,8903,204,791212,813Mar 06 08:00 PM
MOY JEFFREYSVP, OperationsMar 04Option Exercise6.335,00031,650192,485Mar 06 07:54 PM
GREGG TERRANCE HCEOMar 04Option Exercise13.1445,000591,250237,813Mar 06 08:00 PM
MOY JEFFREYSVP, OperationsMar 04Sale47.105,000235,500187,485Mar 06 07:54 PM
GREGG TERRANCE HCEOMar 04Sale46.7945,0002,105,338212,813Mar 06 08:00 PM
GREGG TERRANCE HCEOMar 03Option Exercise11.8325,000295,750232,813Mar 04 06:00 PM
GREGG TERRANCE HCEOMar 03Sale44.7425,0001,118,596212,813Mar 04 06:00 PM
MOY JEFFREYSVP, OperationsFeb 28Option Exercise6.332,50015,825189,985Mar 04 05:50 PM
GREGG TERRANCE HCEOFeb 28Option Exercise8.9515,000134,250227,813Mar 04 06:00 PM